Invention Grant
- Patent Title: Combinatorial multidomain mesoporous chips and a method for fractionation, stabilization, and storage of biomolecules
- Patent Title (中): 组合多畴介孔芯片和生物分子分级,稳定和储存的方法
-
Application No.: US12839606Application Date: 2010-07-20
-
Publication No.: US08685755B2Publication Date: 2014-04-01
- Inventor: Mauro Ferrari , Xuewu Liu , Ennio Tasciotti , Ali Bouamrani , Ye Hu
- Applicant: Mauro Ferrari , Xuewu Liu , Ennio Tasciotti , Ali Bouamrani , Ye Hu
- Applicant Address: US TX Austin
- Assignee: The Board of Regents of The University of Texas System
- Current Assignee: The Board of Regents of The University of Texas System
- Current Assignee Address: US TX Austin
- Agency: Parker Highlander PLLC
- Main IPC: G01N33/552
- IPC: G01N33/552 ; B32B5/16 ; B23H3/00 ; C03C15/00

Abstract:
A new fractionation device shows desirable features for exploratory screening and biomarker discovery. The constituent MSCs may be tailored for desired pore sizes and surface properties and for the sequestration and enrichment of extremely low abundant protein and peptides in desired ranges of the mass/charge spectrum. The MSCs are effective in yielding reproducible extracts from complex biological samples as small as 10 μl in a time as short as 30 minutes. They are inexpensive to manufacture, and allow for scaled up production to attain the simultaneous processing of a large number of samples. The MSCs are multiplexed, label-free diagnostic tools with the potential of biological recognition moiety modification for enhanced specificity. The MSCs may store, protect and stabilize biological fluids, enabling the simplified and cost-effective collection and transportation of clinical samples. The MSC-based device may serve as a diagnostic tool to complement histopathology, imaging, and other conventional clinical techniques. The MSCs mediated identification of disease-specific protein signatures may help in the selection of personalized therapeutic combinations, in the real-time assessment of therapeutic efficacy and toxicity, and in the rational modulation of therapy based on the changes in the protein networks associated with the prognosis and the drug resistance of the disease.
Public/Granted literature
Information query
IPC分类: